Meta-analysis of clinical trials of Permixon in the treatment of symptomatic benign prostatic hyperplasia

Peter Boyle, Chris Robertson, Franklin C. Lowe, Claus Roehrborn

Research output: Contribution to journalArticle

94 Citations (Scopus)

Abstract

Objectives. Permixon is a compound extracted from the fruit of the American dwarf palm tree, Serenoa repens. Controversy regarding the use of phytotherapeutic agents in men with lower urinary tract symptoms suggestive of benign prostatic hyperplasia is significant. We analyzed all available clinical trial data of the Permixon preparation to determine its clinical efficacy compared with placebo. Methods. All published clinical trial data on Permixon (11 randomized clinical trials and 2 open label trials), involving 2859 patients, were used. These trials were disparate in size (from 22 to 592 patients) and duration (from 21 to 180 days). Peak urinary flow rate and nocturia were the two common end points. The statistical analysis was based on a random effects meta-analysis. Results. The average ± SE placebo effect on the peak urinary flow rate was an increase of 0.51 ± 0.51 mL/s. The estimated effect of Permixon was a further increase of 2.20 ± 0.51 mL/s (P

Original languageEnglish (US)
Pages (from-to)533-539
Number of pages7
JournalUrology
Volume55
Issue number4
DOIs
StatePublished - Apr 2000
Externally publishedYes

Fingerprint

Prostatic Hyperplasia
Meta-Analysis
Clinical Trials
Serenoa
Nocturia
Lower Urinary Tract Symptoms
Placebo Effect
Therapeutics
Fruit
Randomized Controlled Trials
Placebos
Permixon

ASJC Scopus subject areas

  • Urology

Cite this

Meta-analysis of clinical trials of Permixon in the treatment of symptomatic benign prostatic hyperplasia. / Boyle, Peter; Robertson, Chris; Lowe, Franklin C.; Roehrborn, Claus.

In: Urology, Vol. 55, No. 4, 04.2000, p. 533-539.

Research output: Contribution to journalArticle

Boyle, Peter ; Robertson, Chris ; Lowe, Franklin C. ; Roehrborn, Claus. / Meta-analysis of clinical trials of Permixon in the treatment of symptomatic benign prostatic hyperplasia. In: Urology. 2000 ; Vol. 55, No. 4. pp. 533-539.
@article{7050bd7022d046a490dfaee69144ccc3,
title = "Meta-analysis of clinical trials of Permixon in the treatment of symptomatic benign prostatic hyperplasia",
abstract = "Objectives. Permixon is a compound extracted from the fruit of the American dwarf palm tree, Serenoa repens. Controversy regarding the use of phytotherapeutic agents in men with lower urinary tract symptoms suggestive of benign prostatic hyperplasia is significant. We analyzed all available clinical trial data of the Permixon preparation to determine its clinical efficacy compared with placebo. Methods. All published clinical trial data on Permixon (11 randomized clinical trials and 2 open label trials), involving 2859 patients, were used. These trials were disparate in size (from 22 to 592 patients) and duration (from 21 to 180 days). Peak urinary flow rate and nocturia were the two common end points. The statistical analysis was based on a random effects meta-analysis. Results. The average ± SE placebo effect on the peak urinary flow rate was an increase of 0.51 ± 0.51 mL/s. The estimated effect of Permixon was a further increase of 2.20 ± 0.51 mL/s (P",
author = "Peter Boyle and Chris Robertson and Lowe, {Franklin C.} and Claus Roehrborn",
year = "2000",
month = "4",
doi = "10.1016/S0090-4295(99)00593-2",
language = "English (US)",
volume = "55",
pages = "533--539",
journal = "Urology",
issn = "0090-4295",
publisher = "Elsevier Inc.",
number = "4",

}

TY - JOUR

T1 - Meta-analysis of clinical trials of Permixon in the treatment of symptomatic benign prostatic hyperplasia

AU - Boyle, Peter

AU - Robertson, Chris

AU - Lowe, Franklin C.

AU - Roehrborn, Claus

PY - 2000/4

Y1 - 2000/4

N2 - Objectives. Permixon is a compound extracted from the fruit of the American dwarf palm tree, Serenoa repens. Controversy regarding the use of phytotherapeutic agents in men with lower urinary tract symptoms suggestive of benign prostatic hyperplasia is significant. We analyzed all available clinical trial data of the Permixon preparation to determine its clinical efficacy compared with placebo. Methods. All published clinical trial data on Permixon (11 randomized clinical trials and 2 open label trials), involving 2859 patients, were used. These trials were disparate in size (from 22 to 592 patients) and duration (from 21 to 180 days). Peak urinary flow rate and nocturia were the two common end points. The statistical analysis was based on a random effects meta-analysis. Results. The average ± SE placebo effect on the peak urinary flow rate was an increase of 0.51 ± 0.51 mL/s. The estimated effect of Permixon was a further increase of 2.20 ± 0.51 mL/s (P

AB - Objectives. Permixon is a compound extracted from the fruit of the American dwarf palm tree, Serenoa repens. Controversy regarding the use of phytotherapeutic agents in men with lower urinary tract symptoms suggestive of benign prostatic hyperplasia is significant. We analyzed all available clinical trial data of the Permixon preparation to determine its clinical efficacy compared with placebo. Methods. All published clinical trial data on Permixon (11 randomized clinical trials and 2 open label trials), involving 2859 patients, were used. These trials were disparate in size (from 22 to 592 patients) and duration (from 21 to 180 days). Peak urinary flow rate and nocturia were the two common end points. The statistical analysis was based on a random effects meta-analysis. Results. The average ± SE placebo effect on the peak urinary flow rate was an increase of 0.51 ± 0.51 mL/s. The estimated effect of Permixon was a further increase of 2.20 ± 0.51 mL/s (P

UR - http://www.scopus.com/inward/record.url?scp=0034058050&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0034058050&partnerID=8YFLogxK

U2 - 10.1016/S0090-4295(99)00593-2

DO - 10.1016/S0090-4295(99)00593-2

M3 - Article

VL - 55

SP - 533

EP - 539

JO - Urology

JF - Urology

SN - 0090-4295

IS - 4

ER -